Anti-inflammatory Medication Adherence and Cost and Utilization of Asthma Care in a Commercially Insured Population

References

• National Center for Health Statistics. Asthma Prevalence, Health Care Use and Mortality 2002. Available at: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm, Last accessed June 23, 2007.
   Google Scholar
• Halterman J, Yoos H, Sidora K. Medication use and health care contacts among symptomatic children with asthma. Ambul Pediatr 2001; 1:275–279.
   PubMedGoogle Scholar
• Mangione-Smith R, DeCristofaro A, Setodji C, Keesey J. The quality of ambulatory care delivered to children in the United States. N Engl J Med 2007; 357:1515–1548.
   PubMed Web of Science ®Google Scholar
• The Asthma and Allergy Foundation of America and The National Pharmaceutical Council. Ethnic Disparities in the Burden and Treatment of Asthma 2005. Available from: http://www.aafa.org/, Last accessed December 6, 2006.
   Google Scholar
• Joshi A, Madhavan S. Association of medication adherence with workplace productivity and health-related quality of life in patients with asthma. J Asthma 2006; 43:521–526.
   PubMed Web of Science ®Google Scholar
• Adamson D, Chang S, Hanse L. Health Research Data for the Real World: The MarketScan Databases. Thomson Medstat; 2006.
   Google Scholar
• Maier W, Arrighi H, Morray B, Llewllyn C, Redding G. The impact of asthma and asthma-like illness in Seattle school children. J Clin Epidemiol 1998; 51:557–568.
   PubMed Web of Science ®Google Scholar
• Mattke S, Jain A, Sloss E. Effect of disease management on prescription drug treatment: what is the right quality measure? Dis Manage 2007; 10:91–100.
   PubMedGoogle Scholar
• Hess L, Raebel M, Conner D, Malone D. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40:1280–1288.
   PubMed Web of Science ®Google Scholar
• Cabana M, Slish K, Nan B, Clark N. Limits of the HEDIS criteria in determining asthma severity in children. Pediatrics 2005; 114:1049–1055.
   Web of Science ®Google Scholar
• Allen-Ramey F, Duong P, Goodman D. Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy Asthma Proc 2003; 24:43–51.
   PubMed Web of Science ®Google Scholar
• Ozminkowski R, Wang S, Marder W. Cost implications for the use of inhaled anti-inflammatory medications in the treatment of asthma. Pharmacoeconomics 2000; 18:253–264.
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Nelsen LM, Kulkami AS, Pleasants RA, Whitmire JT, Schechter MS. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population: a retrospective data analysis. J Asthma 2005; 1:35–40.
   Google Scholar
• Ducharme F, di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD002314. DOI: 10.1002/14651858.CD002314.pub2.
   Google Scholar
• Orsini L, Limpa-Amara S, Crown W, Stanford R, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004; 92:523–529.
   PubMed Web of Science ®Google Scholar
• Halpen M, Khan Z, Stanford R, Spayde K, Golubiewski M. Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment—a meta-analysis. J Fam Pract 2003; 52:382–389.
   PubMed Web of Science ®Google Scholar
• Stempel D, Kruzikas D, Manjunath R. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast. J Pediatr 2007; 150:162–167.
   PubMed Web of Science ®Google Scholar
• Heaton P. Cost effectiveness of leukotriene modifiers in adults with asthma. Pharmacoeconomics 2006; 24:727–742.
   PubMed Web of Science ®Google Scholar
• Stempel D, Stoloff S, Carranza Rosenzweig J, Stanford R, Ryskina K, Legorreta A. Adherence to asthma controller medication regimens. Respir Med 2006; 99:1263–1267.
   Web of Science ®Google Scholar
• Bukstein D, Henk H. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001; 23:1589–15100.
   PubMed Web of Science ®Google Scholar
• Heckman J. Sample selection bias as a specification error. Econometria 1976; 47:153–161.
   Web of Science ®Google Scholar
• Mattke S, Seid M, Ma S. Evidence for the effect of disease management: is $1 billion a year a good investment? Am J Managed Care 2007; 13:670–676.
   PubMed Web of Science ®Google Scholar
• Schmier J, Leidy N. The complexity of treatment adherence in adults with asthma: challenges and opportunities. J Asthma 1998; 35:455–472.
   PubMed Web of Science ®Google Scholar
• Price D, Ben-Joseph R, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the UK. Respir Med 2001; 95:83–89.
   PubMed Web of Science ®Google Scholar
• Stempel D, Mauskopf J, McLaughlin T, Yazdani C, Stanford R. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227–234.
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343:332–336.
   PubMed Web of Science ®Google Scholar
• Donahue J, Weiss S, Livingston J, Goetsch M, Greineder D, Platt R. Inhaled steriods and the risk of hospitalization for asthma. JAMA 1997; 277:887–891.
   PubMed Web of Science ®Google Scholar
• Bukstein D, Henk H, Luskin A. A comparison of asthma-related expenditures for patients started on montelukast versus fluticason propionate as monotherapy. Clin Therapeut 2001; 23:1589–1600.
   PubMed Web of Science ®Google Scholar